【摘要】 基于驱动基因检测基础上的靶向药物治疗是目前晚期非小细胞肺癌的重要治疗手段。组织标本是驱动基因检测的金标准,但多数晚期肺癌患者无法获得足够的组织标本进行基因检测。探索组织标本替代品进行驱动基因检测是当前临床的热点问题。本文对驱动基因检测的组织替代标本进行综述。更多还原

【Abstract】 Target treatment based on driver genes in advanced non-small cell lung cancer is very important currently. Tumor tissues is the gold standard for driver genes testing. However, most of patients could not get the gene information for lack of enough tissues. To explore the tissue specimens alternatives is a hot spot in clinical work. This report reviews the tissue specimen alternatives of driver gene testing in non-small cell lung cancer.更多还原